Azitra (NYSEAMERICAN:AZTR) Stock Price Down 2.2% – Time to Sell?

Azitra, Inc. (NYSEAMERICAN:AZTR)’s share price dropped 2.2% on Thursday . The company traded as low as $0.71 and last traded at $0.72. Approximately 121,889 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 153,158 shares. The stock had previously closed at $0.74.

Analysts Set New Price Targets

Separately, Maxim Group lowered their price target on shares of Azitra from $13.32 to $4.00 and set a “buy” rating for the company in a report on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $4.00.

Azitra Trading Down 2.2%

The business’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $1.50.

Institutional Trading of Azitra

A hedge fund recently raised its stake in Azitra stock. National Bank of Canada FI boosted its holdings in shares of Azitra, Inc. (NYSEAMERICAN:AZTR) by 175.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 110,000 shares of the company’s stock after acquiring an additional 70,000 shares during the period. National Bank of Canada FI owned 0.88% of Azitra worth $34,000 as of its most recent filing with the SEC. 11.16% of the stock is owned by institutional investors and hedge funds.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.